James Wylie is an accredited Consultant Clinical Oncologist, having trained in London , Manchester and Toronto Canada. His NHS practice is at the Christie Hospital Manchester, he is also the lead of the UK multi-institutional prostate brachytherapy database and a member of the British Urological Group.
James has a special interest in the radiation, chemotherapy and hormone treatment options for men with all stages of prostate and bladder cancer. He also has experience in caring for men with early stage testis cancer.
James is at the forefront of radiotherapy technologies and is particularly experienced in prostate brachytherapy (both “seed” brachytherapy and high dose rate brachytherapy [HDR]) and intensity-modulated radiotherapy (IMRT). The prostate brachytherapy service started in 2000. To date, the team have treated over 1000 patients and have an in-house database recording excellent outcomes and a quick return to normal activities
Laterly the HDR program began in 2008 and has now treats 2 patients per week. The HDR technique involves a single HDR treatment, which is unique in the U.K. and maximises patient convenience whilst exploiting the unique sensitivity of prostate cancer to large doses of radiotherapy.
He also has expertise in bladder preservation strategies involving combined chemotherapy and radiotherapy, which, in carefully selected cases may allow preservation of the bladder without need for surgical removal.
James is also an active recruiter into most national UK trials into prostate and bladder cancer and he is also on the trial committee of one national chemotherapy trial in prostate cancer.